Seeking Alpha

Allergan (AGN -2.8%) dips on a Goldman downgrade to Neutral this morning. The firm cites a lack...

Allergan (AGN -2.8%) dips on a Goldman downgrade to Neutral this morning. The firm cites a lack of near-term catalysts, saying it now sees greater upside to Forest Labs (FRX), with its potential for significant restructuring/strategic alternatives and pending new management changes later this year.
Comments (1)
  • richardod
    , contributor
    Comments (70) | Send Message
     
    Allergan Inc. (NYSE: AGN) was downgraded by analysts at Goldman Sachs from a "buy" rating to a "neutral" rating. They now have a $110.00 price target on the stock. 14.3% Upside.- must be a buy after
    these losses?
    21 Jun 2013, 02:29 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs